{"entity":{"id":"nct06908772","kind":"trial","name":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","aka":[],"tldr":"A phase 2/3 trial in lung cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.","summary":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients is a phase 2/3, randomised interventional study registered as NCT06908772 by Shanghai JMT-Bio Inc., with a registry enrolment figure of 390 participants, started 2025-04-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Glumetinib Tablets; Osimertinib Mesylate Tablets; Glumetinib Tablets Placebo. Conditions listed: Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression. Primary outcome: Phase 2：ORR as assessed by IRC. Lung eligibility wording from the registry: \"Patients with NSCLC who have unresectable locally advanced or metastatic disease; 4\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06908772","url":"https://clinicaltrials.gov/study/NCT06908772"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc","met-altered-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06908772","phase":"2/3","setting":"A Multicenter Phase II/III Clinical Study on the Efficacy and Safety of Glumetinib Combined With Osimertinib as First-Line Treatment in Non-Small Cell Lung Cancer Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression","sponsor":"Shanghai JMT-Bio Inc.","enrolled":390,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06908772/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}